Literature DB >> 21793733

Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice.

Kaustuv Banerjee1, Elizabeth Michael, Dirk Eggink, Thijs van Montfort, Amanda B Lasnik, Kenneth E Palmer, Rogier W Sanders, John P Moore, Per Johan Klasse.   

Abstract

To assess the influence of mannosylated glycans on the immunogenicity of human immunodeficiency virus type 1 (HIV-1) Env proteins, we immunized mice with monomeric gp120 in the presence and absence of the mannose-binding protein, griffithsin (GRFT). For comparison, other groups of mice received the nonglycosylated HIV-1 Gag protein, with and without GRFT. Coimmunization with GRFT increased the anti-gp120 IgG reactivity significantly, but had no effect on the anti-Gag response. We also investigated the IgG response to GRFT and found that gp120, but not Gag, enhanced its immunogenicity. For both proteins, IgG1 antibodies dominated the IgG response, with IgG2b as the next most prevalent subclass. We conclude that gp120-GRFT complexes are more immunogenic than the free proteins, for both components, and that occluding the mannose moieties on monomeric gp120 can improve the humoral immune response to this protein.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793733      PMCID: PMC3275927          DOI: 10.1089/aid.2011.0101

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  32 in total

Review 1.  Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects?

Authors:  P J Klasse; John P Moore
Journal:  Virology       Date:  2004-05-20       Impact factor: 3.616

2.  Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.

Authors:  Katie J Doores; Camille Bonomelli; David J Harvey; Snezana Vasiljevic; Raymond A Dwek; Dennis R Burton; Max Crispin; Christopher N Scanlan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

3.  Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component.

Authors:  Barry R O'Keefe; Fakhrieh Vojdani; Viviana Buffa; Robin J Shattock; David C Montefiori; James Bakke; Jon Mirsalis; Anna-Lisa d'Andrea; Steven D Hume; Barry Bratcher; Carrie J Saucedo; James B McMahon; Gregory P Pogue; Kenneth E Palmer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-30       Impact factor: 11.205

Review 4.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions.

Authors:  Laura M Walker; Dennis R Burton
Journal:  Curr Opin Immunol       Date:  2010-03-17       Impact factor: 7.486

5.  Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans.

Authors:  D Cameron Dunlop; Camille Bonomelli; Fatma Mansab; Snezana Vasiljevic; Katie J Doores; Mark R Wormald; Angelina S Palma; Ten Feizi; David J Harvey; Raymond A Dwek; Max Crispin; Christopher N Scanlan
Journal:  Glycobiology       Date:  2010-02-24       Impact factor: 4.313

6.  Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function.

Authors:  Dirk Eggink; Mark Melchers; Manfred Wuhrer; Thijs van Montfort; Antu K Dey; Benno A Naaijkens; Kathryn B David; Valentin Le Douce; André M Deelder; Kenneth Kang; William C Olson; Ben Berkhout; Cornelis H Hokke; John P Moore; Rogier W Sanders
Journal:  Virology       Date:  2010-03-21       Impact factor: 3.616

7.  Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.

Authors:  Kaustuv Banerjee; Sofija Andjelic; Per Johan Klasse; Yun Kang; Rogier W Sanders; Elizabeth Michael; Robert J Durso; Thomas J Ketas; William C Olson; John P Moore
Journal:  Virology       Date:  2009-05-02       Impact factor: 3.616

8.  Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.

Authors:  Peter F Wright; Jiri Mestecky; M Juliana McElrath; Michael C Keefer; Geoffrey J Gorse; Paul A Goepfert; Zina Moldoveanu; David Schwartz; Paul W Spearman; Raphaelle El Habib; Michele D Spring; Yuwei Zhu; Carol Smith; Jorge Flores; Kent J Weinhold
Journal:  J Infect Dis       Date:  2004-03-15       Impact factor: 5.226

9.  Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae.

Authors:  Barry R O'Keefe; Barbara Giomarelli; Dale L Barnard; Shilpa R Shenoy; Paul K S Chan; James B McMahon; Kenneth E Palmer; Brian W Barnett; David K Meyerholz; Christine L Wohlford-Lenane; Paul B McCray
Journal:  J Virol       Date:  2009-12-23       Impact factor: 5.103

10.  Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity.

Authors:  Tinoush Moulaei; Shilpa R Shenoy; Barbara Giomarelli; Cheryl Thomas; James B McMahon; Zbigniew Dauter; Barry R O'Keefe; Alexander Wlodawer
Journal:  Structure       Date:  2010-09-08       Impact factor: 5.006

View more
  21 in total

1.  The griffithsin dimer is required for high-potency inhibition of HIV-1: evidence for manipulation of the structure of gp120 as part of the griffithsin dimer mechanism.

Authors:  Jie Xue; Bart Hoorelbeke; Ioannis Kagiampakis; Borries Demeler; Jan Balzarini; Patricia J Liwang
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

Review 2.  Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?

Authors:  P J Klasse; Gabriel Ozorowski; Rogier W Sanders; John P Moore
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

3.  The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells.

Authors:  Kabamba B Alexandre; Elin S Gray; Hazel Mufhandu; James B McMahon; Ereck Chakauya; Barry R O'Keefe; Rachel Chikwamba; Lynn Morris
Journal:  Virology       Date:  2011-12-29       Impact factor: 3.616

4.  Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.

Authors:  Rafael S Depetris; Jean-Philippe Julien; Reza Khayat; Jeong Hyun Lee; Robert Pejchal; Umesh Katpally; Nicolette Cocco; Milind Kachare; Evan Massi; Kathryn B David; Albert Cupo; Andre J Marozsan; William C Olson; Andrew B Ward; Ian A Wilson; Rogier W Sanders; John P Moore
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

5.  Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin.

Authors:  Robert P de Vries; Cornelis H Smit; Erwin de Bruin; Alan Rigter; Erik de Vries; Lisette A H M Cornelissen; Dirk Eggink; Nancy P Y Chung; John P Moore; Rogier W Sanders; Cornelis H Hokke; Marion Koopmans; Peter J M Rottier; Cornelis A M de Haan
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

6.  HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells.

Authors:  Nancy P Y Chung; Katie Matthews; Per Johan Klasse; Rogier W Sanders; John P Moore
Journal:  J Immunol       Date:  2012-10-24       Impact factor: 5.422

7.  Human plasmacytoid dendritic cells efficiently capture HIV-1 envelope glycoproteins via CD4 for antigen presentation.

Authors:  Kerrie J Sandgren; Anna Smed-Sörensen; Mattias N Forsell; Martina Soldemo; William C Adams; Frank Liang; Leif Perbeck; Richard A Koup; Richard T Wyatt; Gunilla B Karlsson Hedestam; Karin Loré
Journal:  J Immunol       Date:  2013-05-31       Impact factor: 5.422

Review 8.  A Blueprint for HIV Vaccine Discovery.

Authors:  Dennis R Burton; Rafi Ahmed; Dan H Barouch; Salvatore T Butera; Shane Crotty; Adam Godzik; Daniel E Kaufmann; M Juliana McElrath; Michel C Nussenzweig; Bali Pulendran; Chris N Scanlan; William R Schief; Guido Silvestri; Hendrik Streeck; Bruce D Walker; Laura M Walker; Andrew B Ward; Ian A Wilson; Richard Wyatt
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

9.  Myomedin scaffold variants targeted to 10E8 HIV-1 broadly neutralizing antibody mimic gp41 epitope and elicit HIV-1 virus-neutralizing sera in mice.

Authors:  Milan Kuchař; Petr Kosztyu; Veronika Daniel Lišková; Jiří Černý; Hana Petroková; Eliška Vróblová; Michal Malý; Lucie Vaňková; Michal Křupka; Leona Rašková Kafková; Pavlína Turánek Knotigová; Jarmila Dušková; Jan Dohnálek; Josef Mašek; Jaroslav Turánek; Milan Raška; Petr Malý
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

10.  Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.

Authors:  Gözde Isik; Thijs van Montfort; Nancy P Y Chung; John P Moore; Rogier W Sanders
Journal:  J Immunol       Date:  2014-04-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.